Oscotec

Focus: Oscotec is a Korea-based biotech company developing small molecules with novel mechanisms across immunology, oncology, neurology, and hematology. The company operates as a pre-revenue biotech with an early-stage pipeline focused on differentiated mechanisms.

Immunology Oncology Neurology Hematology

Profile data last refreshed 2d ago · AI intelligence enriched 1w ago

Open Jobs

About Oscotec

AI assessmentNot Hiring

No open roles listed right now. Follow Oscotec to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

9 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

.[14C]-SKI-O-703

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT05042986A Study of the Absorption, Metabolism, and Excretion of [14C]-SKI-O-703 Following a Single Oral Dose in Healthy Male Subjects

Phase 1

Help build intelligence for Oscotec

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Exposure to four high-value therapeutic areas (immunology, oncology, neurology, hematology) with multiple mechanistic approaches
Ground-floor opportunity at an early-stage biotech where individual contributions directly shape company trajectory
Portfolio includes multi-indication potential (SKI-O-703 in rheumatoid arthritis and immune thrombocytopenia; SKI-G-801 in AML and solid tumors)

Watch Out For

Pre-revenue stage with no public financial data; cash runway and funding stability are undisclosed risk factors
Early pipeline maturity (6 Phase 1, 2 Phase 2, 0 Phase 3 programs) means clinical success and regulatory approval are years away with high attrition risk
No active job openings currently listed; hiring freeze or limited expansion capacity may limit near-term career mobility

Generated by Claude from Oscotec's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

SKI-O-703 capsule

Arthritis, Rheumatoid

Phase 1

Clinical Trials (1)

NCT03315494Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy Volunteers

Phase 1

SKI-O-703 capsule

Rheumatoid Arthritis

Phase 1

Clinical Trials (1)

NCT02717988Safety, Tolerability, and Pharmacokinetics of a Single Oral Dose of SKI-O-703 in Healthy Volunteers

Phase 1

SKI-G-801

Acute Myeloid Leukemia

Phase 1

Clinical Trials (1)

NCT03564288Study to Find a Safe and Effective Dose of SKI-G-801 in the Treatment of Patients With Acute Myeloid Leukemia (AML)

Phase 1

OCT-598

Solid Tumor

Phase 1

Clinical Trials (1)

NCT07358806Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors

Phase 1

ADEL-Y01 - healty participants

Alzheimer Disease

Phase 1

SKI-G-801

Advanced Solid Tumor

Phase 1

Clinical Trials (1)

NCT05971862A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SKI-G-801 in Patients With Advanced Solid Tumors

Phase 1

SKI-O-703

Rheumatoid Arthritis

Phase 2

Clinical Trials (1)

NCT04057118A Study to Evaluate the Effectiveness and Safety of SKI-O-703 in Patients Experiencing Active Rheumatoid Arthritis Despite Treatment With Conventional Therapies.

Phase 2

SKI-O-703

Immune Thrombocytopenia

Phase 2

Clinical Trials (1)

NCT04056195Study of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP)

Phase 2